single200MG
L-Carnitine
200MG Protocol
L-Carnitine 200MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks with continued monitoring
Reconstitution
2.0 mL BAC water
Supports fat metabolism by facilitating mitochondrial fatty-acid oxidation
Modest weight-management effects reported in meta-analyses (oral literature cited)
May improve exercise performance and reduce fatigue in certain populations
SC route bypasses gut conversion to TMAO (as described)
Good tolerability reported in clinical contexts for parenteral administration
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 50 mg | 50 |
| 2 | Weeks 3–8 | 100 mg | 100 |
| 3 | Weeks 9–12 | 100 mg | 100 |
Inject once daily
8–12 weeks; optional extension to 16 weeks with continued monitoring
L-carnitine is described as a metabolism-support compound synthesized from lysine and methionine that is essential for transporting long-chain fatty acids into mitochondria for β-oxidation. The protocol explains that it functions as a cofactor for the carnitine palmitoyltransferase (CPT) system, effectively shuttling fats across mitochondrial membranes so they can be converted into ATP—especially relevant during prolonged exercise or caloric restriction. The page also contrasts routes of administration: oral L-carnitine is described as having low bioavailability at high doses and can be converted by gut microbiota into trimethylamine (TMA), which is then converted to TMAO, a metabolite linked in the literature to cardiovascular risk. In contrast, subcutaneous (or IV) delivery is presented as providing 100% bioavailability while bypassing gut conversion, potentially reducing TMAO-related concerns. The protocol summarizes evidence for modest weight-management effects, improved exercise capacity in certain populations, and good tolerability even with higher-dose parenteral use.
Injection-site reactions (mild redness/swelling/irritation)
Gastrointestinal effects are primarily associated with high-dose oral use (nausea/diarrhea/fishy odor)
SC route minimizes these (per page)
Generally well tolerated in parenteral clinical use described
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)